.

Pharmaceutical Business Intelligence

  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information
  • Set up watchlists for daily email updates

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

DrugPatentWatch Database Preview

CHILDREN'S ALLEGRA ALLERGY Drug Profile

« Back to Dashboard

Which patents cover Children's Allegra Allergy, and what substitute generic drugs are available?

Children's Allegra Allergy is a drug marketed by Sanofi Aventis Us and is included in three NDAs. There are four patents protecting this drug.

This drug has seventy-two patent family members in forty countries.

The generic ingredient in CHILDREN'S ALLEGRA ALLERGY is fexofenadine hydrochloride. There are twenty-three drug master file entries for this compound. One hundred and three suppliers are listed for this compound. There are five tentative approvals for this compound. Additional details are available on the fexofenadine hydrochloride profile page.

Summary for Tradename: CHILDREN'S ALLEGRA ALLERGY

Patents:4
Applicants:1
NDAs:3
Suppliers / Packagers: see list7
Bulk Api Vendors: see list60
Clinical Trials: see list2,868
Patent Applications: see list1,248
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:CHILDREN'S ALLEGRA ALLERGY at DailyMed

Pharmacology for Tradename: CHILDREN'S ALLEGRA ALLERGY

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-002Jan 24, 2011OTCYesYes6,037,353► Subscribe ► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-005Jan 24, 2011OTCYesNo6,037,353*PED► SubscribeY► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-002Jan 24, 2011OTCYesYes6,723,348► SubscribeY ► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373-001Jan 24, 2011OTCYesYes6,037,353*PED► SubscribeY► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373-001Jan 24, 2011OTCYesYes8,933,097► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: CHILDREN'S ALLEGRA ALLERGY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-005Jan 24, 20116,187,791*PED► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL021909-002Jan 24, 20115,578,610► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-005Jan 24, 20117,135,571*PED► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
SUSPENSION;ORAL201373-001Jan 24, 20116,399,632*PED► Subscribe
Sanofi Aventis Us
CHILDREN'S ALLEGRA ALLERGY
fexofenadine hydrochloride
TABLET;ORAL020872-005Jan 24, 20115,932,247*PED► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: CHILDREN'S ALLEGRA ALLERGY

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,187,791 Method of providing an antihistaminic effect in a hepatically impaired patient► Subscribe
6,399,632 Method of providing an antihistaminic effect in a hepatically impaired patient► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: CHILDREN'S ALLEGRA ALLERGY

Country Document Number Estimated Expiration
European Patent Office1458387► Subscribe
Russian Federation2008128418► Subscribe
China101849917► Subscribe
New Zealand568943► Subscribe
Germany60213861► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc